CLRB
CLRB
NASDAQ · Biotechnology

Cellectar Biosciences Inc

$1.83
+0.03 (+1.67%)
As of Sep 28, 10:40 PM ET ·
Analyst Consensus
Strong Buy
10
Analysts
Moderate
Coverage
Buy 9 90%
Hold 1 10%
Sell 0 0%
Price Target
Analyst Price Target +2,155.7% upside
Low Target $32.58
Average Target $41.28
High Target $58.47
Current Price $1.83
Current
$1.83
Target
$41.28
$32.58 $41.28 avg $58.47
Scenario Analysis
Bear Case
$32.58
1,680.3%
Low target
Base Case
$41.28
+2,155.7%
Avg target
Bull Case
$58.47
+3,095.1%
High target
Risk/Reward
1.8x
Balanced
Price in Context
52-Week High
$6.52
-71.9% from high
52-Week Low
$1.96
+-6.6% from low
Target vs 52W High
$41.28
+533.1% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 39 82% $257.58 -3.3%
AMGN
Amgen Inc
Hold 43 47% $190.87 -54.4%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +138.3%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 36 81% $438.34 -16.9%
REGN
Regeneron Pharmaceuticals
Buy 38 68% $76.80 -89.8%
MRNA
Moderna Inc
Hold 30 37% $149.45 -24.2%
NTRA
Natera Inc
Strong Buy 30 87% $142.91 -65.3%
RVMD
Revolution Medicines Inc
Strong Buy 28 93% $114.11 -43.4%